ARE should gain from the solid demand for top-quality life science assets in key markets, though a vast development outlay ...
U.S. equities were mixed at midday as the Federal Reserve's favored measure of inflation was lower than anticipated.
The first new kind of treatment for schizophrenia patients in decades is arriving. The U.S. Food and Drug Administration ...
U.S. stock indexes are drifting around their records as hopes hold that the economy can pull off the feat of getting ...
The US Food and Drug Administration has approved Cobenfy, which is owned by pharmaceutical firm Bristol Myers Squibb.
Bristol Myers Squibb received U.S. Food and Drug Administration (FDA) approval on Thursday for its groundbreaking ...
Bristol Myers trades higher after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter ...
The blue-chip Dow rose on Friday to hit an intraday record and small-cap stocks outperformed after a benign inflation report ...
Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback